SOL578
Haematological & Brain Cancers
Phase 1Active
Key Facts
About Sentinel Oncology
Sentinel Oncology is a private, preclinical-stage biotech company leveraging its medicinal chemistry expertise to develop targeted small molecule inhibitors for cancers with high unmet need, especially those affecting the brain. Its pipeline features three late-stage preclinical programs, with its lead asset, SOL578 (a Chk1 inhibitor), having entered Phase 1 trials in 2023 via a licensing agreement with PharmaEngine. The company employs a collaborative business model, partnering with pharmaceutical and biotech organizations to advance and commercialize its programs.
View full company profile